
|Videos|January 20, 2021
Ovarian Cancer: FDA Approved PARP Inhibitors
Author(s)Thomas Herzog, MD
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
T-DXd 5.4 mg/kg Combos Yield Fewer Grade ≥3 AEs in HER2+ Gastric Cancers
2
Personalized Cancer Vaccine/Pembrolizumab Feasible, Effective in Newly Diagnosed GBM
3
Teclistamab Monotherapy Improves PFS and OS in Relapsed/Refractory Myeloma
4
Adjuvant Giredestrant Improves Invasive DFS in ER+, HER2– Early Breast Cancer
5
































































